Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Aetna rhinometry policy coverage update | OpenPaye…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0700

    Rhinometry and Rhinomanometry

    Customize your policy alerts

    Sign up for Aetna Policy 0700 alerts

    Get alerted when Policy 0700 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the coverage stance for rhinomanometry, acoustic rhinometry, and optical rhinometry for Aetna members; it affects providers ordering or billing for nasal function testing.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyRhinometry and Rhinomanometry
    Policy CodePolicy 0700
    Change TypeNo material changes
    Effective Date03/01/2005
    Last ReviewSep 20, 2023
    Next Review Date07/25/2024
    Key ActionWhen ordering rhinomanometry or related nasal function studies, document clinical indication and how test results will change patient management; include CPT 92512 when billing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    92512CPT code listed
    Not establishedEffectiveness
    MultipleStudies summarized
    09/20/2023Last review

    Coverage Criteria and Clinical Use

    Experimental/Investigational

    Experimental/Investigational Determination: Aetna considers rhinomanometry, acoustic rhinometry, and optical rhinometry experimental and investigational because clinical studies have not demonstrated that these tests improve clinical outcomes and the effectiveness of these approaches has not been established.

    Support: policy statement and background noting inadequate evidence and lack of superiority to physical exam, endoscopy, or CT imaging.

    Evidence summary and intended use

    Evidence-based findings and context for clinical interpretation (no explicit coverage decision in this excerpt):

    Evidence summary: Acoustic rhinometry (AR) and rhinomanometry (RMM) show inconsistent correlations with patient‑reported nasal patency; correlations are more likely with unilateral assessments and when obstructive symptoms are present. As single diagnostic tools AR/RMM have limited utility versus anterior rhinoscopy, nasal endoscopy, or imaging and have not been shown to improve selection for medical or surgical management.

    Based on systematic reviews and multiple cohort/observational studies.

    Appropriate clinical contexts

    Use of AR or rhinomanometry may be considered appropriate in select clinical scenarios when objective assessment of nasal patency will inform management:

    Situations supporting use: Pre- and post-operative evaluation for septoplasty or adenoidectomy when objective measures are correlated with validated patient‑reported outcome measures and endoscopic findings; assessment in children when endoscopy is not feasible; evaluation of suspected nasal valve collapse using targeted tests (eg, FRIED or 4‑phase rhinomanometry); use in research settings or clinical trials; adjunct assessment of nasal contribution to lower airway disease in specific populations.

    Derived from cohort studies, specialty reviews, and diagnostic investigations.

    Contexts with limited diagnostic value

    Limitations and caution:

    Contexts with limited utility: Routine ordering of AR or rhinomanometry for all patients with nasal obstruction is not supported because objective measures may not correlate with subjective symptoms; AR/RMM in isolation lack adequate sensitivity and specificity to replace anterior rhinoscopy, nasal endoscopy, or imaging; rhinomanometry is not required in routine cystic fibrosis care and is better reserved for outcome measurement in trials.

    Based on systematic reviews, UpToDate guidance, and observational studies.

    When to use objective nasal patency testing

    Use of objective nasal patency tests in clinical practice

    Selection and interpretation: Objective tests (acoustic rhinometry, rhinomanometry, peak nasal inspiratory flow) should be ordered selectively after specialist evaluation and interpreted alongside validated patient‑reported outcome measures; PNIF is preferred for routine clinical assessment of nasal obstruction, while rhinomanometry and acoustic rhinometry are primarily useful in research or select clinical scenarios.

    Recommendation supported by UpToDate reviews and systematic review findings.

    Decongestant test criteria for turbinate surgery (pediatrics)

    Using rhinomanometry decongestant testing to select pediatric patients for turbinate surgery

    Pediatric turbinate surgery selection: Perform anterior active rhinomanometry before and after topical nasal decongestant and calculate percent improvement in nasal resistance. Consider surgical turbinate intervention when percent improvement meets preliminary thresholds reported in the YO‑IFOS pediatric study (best overall classification at ~31.66% or higher specificity at 38.88%), and document measured percent improvement along with clinical findings and PROMs.31.66% / 38.88%

    Preliminary cut-offs; findings require further validation; document age stratification and combined clinical assessments when used for surgical decision‑making.

    4-phase rhinomanometry threshold for internal valve collapse

    Diagnosis of internal nasal valve collapse using 4-phase rhinomanometry

    4-phase rhinomanometry diagnostic threshold: Measure the inspiratory loop (hysteresis) area per nostril on 4‑phase rhinomanometry. Use an inspiratory loop area threshold of 17.3 Pa·L·s‑1 to identify internal nasal valve collapse (reported sensitivity 88.3% and specificity 89.9% in the diagnostic case‑control study). Clinical correlation and larger validation studies are required before routine adoption.17.3 Pa L s-1

    Single diagnostic study; Level of Evidence IV.

    Optical rhinometry uses

    Optical rhinometry (ORM) applications and limitations

    ORM challenge testing: ORM has demonstrated correlation with subjective congestion and with acoustic rhinometry measurements during nasal provocation or capsaicin/antigen challenges and may provide real‑time assessment of mucosal response; however, evidence derives from small pilot studies and larger validation is needed before routine clinical use.

    Pilot and small cohort studies report correlations with AR and symptom scores; further research required.

    nFeNO use and threshold

    nFeNO as inflammatory biomarker

    nFeNO diagnostic use: Nasal fractional exhaled nitric oxide (nFeNO) may help predict rhinitis or rhinitis with asthma; one pediatric study reported a diagnostic cut‑off of 662 ppb with good predictive performance, but measurement techniques are not standardized and further methodological validation is needed.662 ppb

    Single pediatric study; interpret cautiously due to technique variability and need for replication.

    The policy lists ICD‑10 diagnosis code ranges that are referenced as not covered for indications in this Clinical Policy Bulletin. These include J01.00‑J01.91 (acute sinusitis), J30.1‑J30.9 (vasomotor and allergic rhinitis), J32.0‑J32.9 (chronic sinusitis), and the specific codes J34.2 (deviated nasal septum) and J34.3 (hypertrophy of nasal turbinates).

    Acoustic rhinometry (AR), rhinomanometry (RMM), and related nasal function tests have variable diagnostic accuracy and have not been shown to be superior to a hands‑on clinical assessment. Systematic reviews and clinical guidance report that these objective tests lack sufficient sensitivity and specificity to replace anterior rhinoscopy, nasal endoscopy, or imaging (CT), and they may be ordered only in select situations after specialist evaluation.

    Rhinomanometry is not required as part of routine cystic fibrosis care. While objective measures can be used as outcome parameters in clinical trials or research settings, the evidence does not support routine use for CF management; instead short clinical symptom questions and endoscopic assessment remain central to CF sinonasal care.

    Comparative studies show that acoustic rhinometry underestimates internal nasal volumes compared with cone‑beam CT (CBCT). In one pediatric cohort mean volumes measured by AR were 6.6 ± 1.9 cm3 versus 8.1 ± 1.5 cm3 by CBCT (a 17.7% difference), indicating known measurement discrepancies between AR and CT that should be considered when interpreting results.

    Aetna considers rhinomanometry, acoustic rhinometry, and optical rhinometry experimental and investigational because available clinical studies have not established that these tests improve patient management or clinical outcomes. Consequently, their clinical utility and effectiveness remain unproven in the peer‑reviewed literature.

    Using acoustic rhinometry or other objective measurements alone as the sole diagnostic modality is not recommended. The literature shows AR and RMM cannot reliably discriminate chronic rhinosinusitis from controls or replace endoscopy/imaging for diagnosing septal deviation without corroborating clinical and endoscopic findings.

    The policy excerpt provides discussion of evidence and utility but does not contain additional explicit phrasing beyond designation of investigational status; there are no other standalone 'not medically necessary' statements in this excerpt.

    Routine ordering of rhinomanometry or acoustic rhinometry for all patients with nasal obstruction is not supported. Objective measures often do not correlate well with patient‑reported symptoms, so these tests should be reserved for selected cases after specialist evaluation and interpreted alongside validated patient‑reported outcome measures.

    Coding and Diagnostic Thresholds

    Primary CPT Codes referencedCPT
    92512Nasal function studies (e.g., rhinomanometry)
    Other related CPT CodesCPT
    31231Nasal and nasal/sinus, diagnostic, endoscopy
    31232Nasal and nasal/sinus, diagnostic, endoscopy
    31233Nasal and nasal/sinus, diagnostic, endoscopy
    31234Nasal and nasal/sinus, diagnostic, endoscopy
    31235Nasal and nasal/sinus, diagnostic, endoscopy
    Related imaging CPT CodesCPT
    70450Computed tomography, head or brain
    70460Computed tomography, head or brain
    70470Computed tomography, head or brain
    ICD-10 codes referenced as related/not coveredICD-10
    J01.00-J01.91Acute sinusitis
    J30.1-J30.9Vasomotor and allergic rhinitis
    J32.0-J32.9Chronic sinusitis
    J34.2Deviated nasal septum
    J34.3Hypertrophy of nasal turbinates
    inv-22: FRIED test cut-off
    FRIED test cut-off-0.008 l/s
    Test purposeDifference between inspiratory and expiratory flow during posterior rhinomanometry to identify nasal valve collapse
    Performance reportedSensitivity 82%; Specificity 59% (Maalouf et al, 2016)
    inv-23: Minimum age for reliable ARM in children
    Minimum reliable age for ARM recordingsGreater than 2 years
    Study populationProspective study of 70 children aged 2 to 5 years (Wartelle et al, 2018)

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization and coverage stance

    Rhinomanometry, acoustic rhinometry, and optical rhinometry are designated experimental and investigational by Aetna; providers should expect that requests for these nasal function studies (CPT 92512) may be denied on that basis.

    Prior Authorization

    Justify clinical utility in prior auth

    When seeking authorization, document the specific clinical context and how AR/RMM results will change patient management because the evidence shows variable diagnostic accuracy and limited utility when used alone.

    Note

    Prior authorization: none specified in excerpt

    This document excerpt does not specify any explicit prior authorization requirements or an authorization process for rhinometry or rhinomanometry.

    Background and Evidence

    Nasal obstruction has multiple causes—including allergic rhinitis, deviated nasal septum, chronic or acute sinusitis and mucosal disease—and diagnosis is primarily clinical. Initial assessment relies on symptoms and physical examination with anterior rhinoscopy or nasal endoscopy to identify anatomic restriction. Objective tests such as acoustic rhinometry and rhinomanometry provide physiologic or anatomic data (cross‑sectional areas, volumes, airway resistance) but have inconsistent correlation with subjective sensation of obstruction and therefore are typically adjunctive rather than primary diagnostic tools.

    Definitions and Test Descriptions

    inv-48: Rhinomanometry definition
    DefinitionMeasurement of nasal airflow and resistance using pressure and flow during breathing to calculate nasal airway resistance (rhinomanometry)
    UseProvides a functional measure of pressure/flow relationships during the respiratory cycle; applied in clinic or laboratory settings
    LimitationsRequires operator and patient cooperation, equipment is not portable and may not yield repeatable results in all patients
    inv-49: Acoustic rhinometry definition (short)
    Definition (short)Objective sonic echo technique using reflected sound to measure cross-sectional area and volume of the nasal passage (acoustic rhinometry)
    CharacteristicGives an anatomic description (MCA and volumes) and requires little patient cooperation

    Policy Dates and History

    Providers should note that this Clinical Policy Bulletin references CPT code 92512 for nasal function studies (e.g., rhinomanometry). The document excerpt does not list specific prior authorization requirements for these tests; providers seeking authorization or making coverage determinations should refer to the plan’s main policy and benefit rules and include the policy review dates (Last Review 09/20/2023, Effective 03/01/2005, Next Review 07/25/2024) when relevant.

    Policy Summary
    PayerAetna
    PolicyRhinometry and Rhinomanometry
    Policy CodePolicy 0700
    Change TypeNo material changes
    Effective Date03/01/2005
    Last ReviewSep 20, 2023
    Next Review Date07/25/2024
    Key ActionWhen ordering rhinomanometry or related nasal function studies, document clinical indication and how test results will change patient management; include CPT 92512 when billing.
    SourceLink
    On This Page
    Coverage Criteria and Clinical UseCoding and Diagnostic ThresholdsProvider Actions, Prior Authorization, and DocumentationBackground and EvidenceDefinitions and Test DescriptionsPolicy Dates and History
    Technique noteUse of a standard nose-piece and single-use surgical filter enabled reliable, serial recordings in preschool children
    inv-24: Rhinomanometry decongestant percent improvement
    Decongestant percent improvement — primary cut-off31.66% (highest overall correct classification, 93.44%)
    Higher-specificity cut-off38.88% (value with highest specificity and highest Youden's index)
    Intended useSelect pediatric patients for turbinate surgery when rhinomanometry percent improvement meets cut-off
    inv-25: 4-phase rhinomanometry inspiratory loop area threshold
    Inspiratory loop area threshold17.3 Pa L s-1
    Diagnostic performanceSensitivity 88.3%; Specificity 89.9% (Gagnieur et al, 2022)
    Clinical noteThreshold derived from 4-phase rhinomanometry to identify internal nasal valve collapse; requires larger validation studies
    inv-26: nFeNO diagnostic cut-off
    nFeNO diagnostic cut-off662 ppb
    Study contextCut-off identified in a pediatric study (6–12 years) as a predictor for rhinitis or rhinitis with asthma
    Methodological noteMeasurement technique not standardized; requires further validation
    Documentation Required

    Document decongestant test when used for turbinate surgery

    For pediatric selection for turbinate surgery, perform anterior active rhinomanometry with and without topical nasal decongestant and document the measured percent improvement in nasal resistance; reported cut-offs include ~31.66% (best overall classification) and 38.88% (highest specificity/Youden index).

    Prior Authorization

    Prior authorization note — refer to broader Aetna guidance

    This excerpt does not list CPT/HCPCS prior-authorization codes or specific authorization rules; providers must refer to the main Aetna policy and plan-specific guidance for any code-based prior authorization requirements.

    Step Therapy

    Step therapy / sequencing: none specified

    No step therapy or sequencing requirements for AR/RMM are specified in this excerpt; the policy states that clinical utility compared with exam, endoscopy, or CT has not been demonstrated.

    Step Therapy

    Step therapy: not specified

    Step therapy is not specified for rhinometry or rhinomanometry in this section of the policy.

    Note

    No action specified

    No provider action specified in this excerpt.

    Note

    Preferred testing pathway — selective use after specialist evaluation

    Order objective nasal patency tests selectively after specialist evaluation and interpret results alongside validated patient-reported outcome measures; use PNIF as the preferred routine screening test while reserving AR/rhinomanometry for select cases or research.

    • PNIF preferred for routine clinical assessment
    • AR/RMM reserved for select clinical scenarios or research
    Note

    No action specified

    No provider action specified in this excerpt.

    Billing Rule

    Coding: include CPT 92512 for nasal function studies

    When billing nasal function studies, include CPT code 92512 (nasal function studies, e.g., rhinomanometry); related diagnostic endoscopy and CT codes are listed elsewhere in the policy for context.

    • Primary code for rhinomanometry: CPT 92512
    • Related codes listed: 31231-31235 (endoscopy); 70450-70470 (CT)
    Documentation Required

    Document objective and subjective measures in septoplasty reports

    For pre- and post-operative septoplasty evaluations, document objective test values (e.g., minimal cross-sectional area, nasal airway resistance, volumes) together with validated patient-reported outcome measures (such as VAS or NOSE) because subjective and objective measures may not correlate consistently.

    • Record MCA/MCSA, nasal resistance, and nasal volume values
    • Record corresponding PROMs (VAS, NOSE) for correlation
    Documentation Required

    Suggested pediatric documentation when using AR

    When using acoustic rhinometry in children, record AR parameters (MCSA, NPV) and correlate findings with nasal endoscopy when possible; ensure reliable ARM recordings using an appropriate nose-piece and single-use filter and note age stratification in reports.

    • Record MCSA and NPV and correlate with endoscopy
    • Use standard nose-piece and single-use filter to ensure reliable recordings, especially in children >2 years
    Documentation Required

    Document decongestant test and combined assessments

    Document rhinomanometry decongestant test results including the percent improvement in nasal resistance and combine these objective findings with subjective assessments (e.g., VAS/Likert) and age/parent assessments when applicable to support surgical decision-making in children.

    • Record percent improvement in nasal resistance (report cut-offs: 31.66% and 38.88%)
    • Combine with subjective scales and parent assessments where applicable
    Note

    Reference policy history and Aetna CPB guidance for coverage determinations

    Reference the policy history and review dates when making coverage determinations and follow Aetna Clinical Policy Bulletin guidance and plan provisions for documentation and member coverage rules.

    Denial Risk

    Experimental/Investigational — anticipate denial risk

    Because Aetna considers AR, RMM, and ORM experimental/investigational, claims for these tests may be denied; include robust documentation of clinical necessity and how results will alter management if requesting authorization or submitting claims.

    • Anticipate potential denial on grounds of experimental/investigational status
    • Provide clear justification of clinical impact when requesting coverage
    Denial Risk

    Diagnostic accuracy limitations — avoid isolated use

    Do not rely on AR or rhinomanometry in isolation for diagnosing nasal septal deviation or making surgical decisions because these tests lack sufficient sensitivity and specificity compared with anterior rhinoscopy, nasal endoscopy, or imaging.

    • Use AR/RMM as adjuncts, not replacements, for endoscopy or imaging
    Note

    No action specified

    No provider action specified in this excerpt.

    Prior Authorization

    Specialist evaluation recommended before ordering objective tests

    Objective nasal measurements should be ordered after specialist evaluation because AR, PNIF, and rhinomanometry may not correlate with subjective obstruction and are most useful when interpreted alongside clinical exam and PROMs.

    • Ensure specialist evaluation documents why objective testing is needed
    • Interpret objective results with validated PROMs and endoscopic findings
    Note

    CPB scope and non-contractual nature — administrative note

    Clinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute offers of coverage; providers remain responsible for treatment decisions and must follow plan-specific coverage rules.

    ApplicationsUsed for assessing nasal cavity geometry and monitoring changes before/after procedures or decongestion
    inv-50: Acoustic rhinometry (AR) detailed
    Detailed definitionObjective method based on sound pulse reflection that determines cross-sectional area as a function of distance and nasal cavity volume, reporting minimal cross-sectional area (MCA) and volumes
    StrengthsEasy to use, requires little patient cooperation, provides repeatable results and correlates with imaging measures of nasal volume
    LimitationsDerivation relies on complex mathematical transformation and theoretical assumptions; as a single instrument it may not discriminate CRS from controls
    inv-51: Rhinomanometry (RMM) detailed
    Detailed definitionTechnique measuring air pressure and airflow rate during breathing to calculate nasal airway resistance (NAR) and airflow; typically active anterior rhinomanometry assesses pressure–flow relationships
    StrengthsProvides a sensitive, nasal-specific functional measure useful in clinic or laboratory assessments and challenge studies
    LimitationsRequires operator, patient cooperation, is not portable, and repeatability may be limited in some patients
    inv-52: Acoustic rhinometry (AR) sonic echo technique
    TechniqueSonic echo technique measuring internal nasal luminal volume and minimum cross-sectional area longitudinally along the nasal passage
    Patient cooperationRequires little patient cooperation and provides repeatable clinic-based results
    Relation to imagingNasal volume measures correlate well with CT or MRI imaging measurements
    inv-53: Rhinomanometry — operator/patient cooperation note
    Cooperation requirementRhinomanometry requires operator and patient cooperation and coordination; not all patients can achieve repeatable results
    Pediatric considerationUse appropriate nose-piece and single-use filter for reliable recordings in young children (ARM feasible >2 years)
    SettingApplicable to clinic or laboratory visits; equipment is not portable for home monitoring
    inv-54: FRIED test definition
    DefinitionDifference between inspiratory and expiratory flow during posterior rhinomanometry proposed to objectively identify nasal valve collapse
    Cut-offFRIED test cut-off = -0.008 l/s
    Clinical useProposed as an objective, easy-to-apply technique to diagnose nasal valve collapse in daily practice
    inv-55: Optical Rhinometry (ORM) definition
    DefinitionOptical Rhinometry (ORM) quantifies light extinction (optical density) to assess nasal blood volume as a measure of nasal patency using an emitter and detector across the nasal bridge
    MechanismOperates via optical spectroscopy measuring absorption of visible and near-infrared light in tissue
    Use caseAllows real-time assessment of mucosal swelling during provocation testing; requires further validation
    inv-56: 4-phase rhinomanometry inspiratory loop area definition
    DefinitionInspiratory loop area: area enclosed by the flow/pressure curve during the two inspiratory phases (hysteresis) in 4-phase rhinomanometry
    Diagnostic thresholdThreshold inspiratory loop area reported at 17.3 Pa L s-1 to reproduce clinical diagnosis of internal valve collapse
    Performance noteReported sensitivity 88.3% and specificity 89.9%; requires larger studies for confirmation
    inv-57: nFeNO definition
    DefinitionNasal fractional exhaled nitric oxide (nFeNO): inflammatory biomarker measured in the nose to predict rhinitis or rhinitis with asthma
    Reported cut-off662 ppb (identified in a pediatric study)
    Interpretation caveatTechnique not standardized across studies; findings require further validation
    inv-58: acoustic rhinometry / rhinomanometry general definition
    General definitionObjective measurement techniques to assess nasal cavity geometry (acoustic rhinometry) and nasal airway resistance/airflow (rhinomanometry)
    Complementary rolesAcoustic rhinometry provides anatomical measures (MCA, volumes); rhinomanometry provides functional pressure–flow measures
    Clinical contextBoth are clinic-based tests used as adjuncts to physical exam/endoscopy or for research; they do not replace endoscopic or imaging evaluation